Strata Critical Medical Inc

Strata Critical Medical Inc(SRTA)股票分析

$4.710

-0.020 (-0.42%)收盘时

Loading chart…
最高
4.780
开盘
4.690
成交量加权均价
4.72
成交量
688.25K
市值
—
最低
4.660
成交额
3.25M
企业价值/息税折旧摊销前利润(TTM)
-93.20

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient.

AI 分析 of Strata Critical Medical Inc (SRTA)

买入

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report, which showed a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and a gross margin of 26.1%. Additionally, the stock is currently priced at $4.54, which is below its Fibonacci resistance levels, suggesting potential for upward movement. However, the forward P/E ratio is notably high at 138.89, indicating that the stock may be overvalued if growth does not materialize as expected.

估值指标

Strata Critical Medical Inc(SRTA)当前预期市盈率为 138.89,5 年平均预期市盈率为 69.75。

预期市盈率

合理
5 年均值 P/E
69.75
当前P/E
138.89
高估
148.88
低估
-9.39

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
92.03
当前EV/EBITDA
-93.20
高估
350.85
低估
-166.80

预期市销率

合理
5 年均值 P/S
1.41
当前P/S
1.27
高估
1.64
低估
1.18

持有 SRTA 的大户

T

Third Point LLC

+ 持有SRTA

-3.14%

3个月收益率

事件时间线

2026-05-06 (ET)

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

2026-03-03 (ET)

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

07:10:00

Raises EBITDA Outlook to $29M-$33M

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

资讯

SRTA 常见问题 —— 由 Alphio AI 解答

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report, which showed a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and a gross margin of 26.1%. Additionally, the stock is currently priced at $4.54, which is below its Fibonacci resistance levels, suggesting potential for upward movement. However, the forward P/E ratio is notably high at 138.89, indicating that the stock may be overvalued if growth does not materialize as expected.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易